BELMONT, Calif., March 3, 2011 /PRNewswire/ -- Ventus Medical, Inc. a privately-held medical device company dedicated to providing novel products to treat sleep-disordered breathing, today announced that it has received CE Mark for its Provent® Sleep Apnea Therapy.
"We are pleased to accomplish this important regulatory milestone. Receiving CE Mark for Provent Therapy will facilitate our international commercialization strategy and allow us to launch this product in selected countries over the next several months," said Peter Wyles, president and chief executive officer of Ventus Medical. "We intend to introduce Provent Therapy internationally in a systematic way through established distributors, focusing on countries with a high prevalence of obstructive sleep apnea. There is a clear need for therapeutic options other than CPAP and Provent Therapy represents an attractive new alternative."
About Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is the most common type of sleep-disordered breathing. It is estimated that one in 20 adults worldwide suffer from sleep apnea, with population-based studies suggesting that certain countries have a higher prevalence of OSA. In those with OSA, the airway collapses during sleep when the muscles, that hold the airway open, relax. People with this disorder can stop breathing while sleeping---in some cases hundreds of times each night---usually for periods of ten seconds or longer. Importantly, many recent studies have shown that people with OSA experience higher rates of car accidents as well as serious health problems including high blood pressure, heart attack, stroke and diabetes.